Luisana Sisca

Chemotherapy Backbone and Outcomes of Immune Checkpoint Inhibitor Combinations Across Solid Tumors: A Pan-Tumor Network Meta-Analysis

Luisana Sisca, Mariam Grazia Polito, Alessio Cortellini, Marco Russano et autres

BACKGROUND: Immune checkpoint inhibitors (ICIs) combined with chemotherapy represent a first-line standard across multiple solid tumors; however, the contribution of chemotherapy backbone to the efficacy of chemo-immunotherapy remains uncertain. METHODS: We conducted a systematic review and network meta-analysis of phase II-III randomized …

it, fr, gb (code pays fourni par la source)

Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials

Mariam Grazia Polito, Luisana Sisca, Davide Caruso, Antonella Cosimati et autres

Introduction: Immunotherapy has reshaped the adjuvant landscape, with several immune checkpoint inhibitors (ICIs) approved in different tumor types. This meta-analysis evaluates the benefit of adjuvant ICIs across solid tumors. Methods: A systematic literature search of PubMed, Embase, the Cochrane Central Register of …

it (code pays fourni par la source)

Corrigendum to “Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: an exploratory imaging-based analysis” [J. Bone Oncol. (2026) 100795]

Mariam Grazia Polito, Consolo Andrea, Cariglia Marcello, Simone Foderaro et autres

Circulating Tumor DNA in Bladder Cancer: Current Clinical Evidence and Emerging Multi-Omics Perspectives—A Narrative Review

Mariam Grazia Polito, Luisana Sisca, Davide Caruso, Antonella Cosimati et autres

Background: Circulating tumor DNA (ctDNA) analysis has emerged as a promising tool for real-time disease monitoring in muscle-invasive bladder cancer (MIBC). This narrative review summarizes current clinical evidence regarding ctDNA across disease stages. Methods: We examine recent translational and clinical findings, incorporating …

it, fr (code pays fourni par la source)

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance

Luisana Sisca, Mariam Grazia Polito, Emy Sisca, Giuseppe Francesco Papalia et autres

Bone metastases are a major complication of advanced solid tumors and are associated with substantial morbidity and reduced survival. Imaging plays a central role in detection and monitoring, yet conventional modalities and qualitative risk scores remain limited by suboptimal specificity and inter-reader …

it, fr, gb (code pays fourni par la source)

Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis

Mariam Grazia Polito, Consolo Andrea, Cariglia Marcello, Simone Foderaro et autres

Background Metastatic burden is a key determinant of prognosis in advanced solid tumors, yet current RECIST 1.1-based assessment does not fully capture total or site-specific disease extent. Emerging evidence suggests that quantitative imaging-derived metrics may improve prognostic stratification beyond binary metastatic classification. …

it, nl, gb (code pays fourni par la source)

Impact of Local Treatment of the Primary Tumor on Overall Survival in De Novo Metastatic Breast Cancer: A Systematic Review and Meta-analysis

Luisana Sisca, Mariam Grazia Polito, Michele Iuliani, Giuseppe Tonini et autres

Background/Aim: The prognostic impact of local treatment (LT) of the primary tumor in patients with de novo metastatic breast cancer (dnMBC) remains unclear. We conducted a systematic review and meta-analysis to evaluate whether surgery and/or radiotherapy of the primary tumor improves overall …

it, fr (code pays fourni par la source)

Toxicities of Antibody–Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management

Luisana Sisca, Mariam Grazia Polito, Arianna Travisani, Fernando Zannino et autres

Background/Objectives: Antibody–drug conjugates (ADCs) have transformed the therapeutic landscape of breast cancer, expanding treatment opportunities across multiple disease settings. However, their increasing clinical use has revealed a heterogeneous spectrum of toxicities that extends beyond conventional chemotherapy-related adverse events. Emerging evidence suggests that …

it, fr (code pays fourni par la source)

Artificial intelligence–enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications

Luisana Sisca, Mariam Grazia Polito, Emy Sisca, Michele Iuliani et autres

Background: Liquid biopsy offers a minimally invasive approach for cancer detection and monitoring, but its diagnostic performance is often limited by low signal abundance and biological noise. Artificial intelligence (AI) has been proposed as a computational framework to integrate heterogeneous and biologically …

it, fr, gb (code pays fourni par la source)

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer

Francois Clement Bidard, Carlos Barrios, Giampaolo Bianchini, Adam Brufsky et autres

In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key …

fr, br, it, us, ca, es, ae, de, be, jp, au, gb, kr, ch (code pays fourni par la source)

Net clinical value of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer: Integrating efficacy heterogeneity and treatment burden.

Luisana Sisca, Mariam Grazia Polito, Alessio Cortellini, Bruno Vincenzi et autres

e12659 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) improve pathological complete response (pCR) rates in early-stage triple-negative breast cancer (TNBC). In curative-intent settings, however, treatment escalation should be guided not only by efficacy signals but also by baseline clinical risk and downstream treatment …

it, gb (code pays fourni par la source)

Defining second-line sequencing in advanced renal cell carcinoma: A systematic review and meta-analysis.

Luisana Sisca, Mariam Grazia Polito, Alessio Cortellini, Bruno Vincenzi et autres

4539 Background: In the absence of head-to-head comparative trials, the optimal sequencing of second-line systemic therapy for advanced renal cell carcinoma (RCC) remains undefined. As immune checkpoint inhibitor (ICI) based regimens now represent the dominant first-line standard, second-line treatment decisions increasingly rely …

it, gb (code pays fourni par la source)